Amgen Buys Medigene Spin-Off Company Catherex
December 23, 2015.
Amgen (Thousand Oaks, CA) has acquired Catherex from Medigene (Munich, Germany) for an upfront payment of $10.5 million.
Medigene will receive about 40 percent of the payments from Amgen, while Catherex shareholders will receive the upfront payment plus milestone payments based on Amgen’s Imlygic, which was approved by FDA in October 2015 for the treatment of advanced, metastatic melanoma. Catherex, located in Philadelphia, PA, was spun off from Medigene in April 2010 with the development of a cancer-killing herpes simplex virus (oHSV).
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
